Difference between revisions of "Gautret P, et al, Int J Antimicrob Agents (2020), cited as Ref 82 in DOI:10.1007/s11886-020-01292-3 (Q10591)"
Jump to navigation
Jump to search
(Created claim: Fifth Author string (P153): Meddeb L, #quickstatements; #temporary_batch_1592503455634) |
(Created claim: Sixth Author string (P154): Mailhe M, #quickstatements; #temporary_batch_1592503575618) |
||
Property / Sixth Author string | |||
+ | Mailhe M | ||
Property / Sixth Author string: Mailhe M / rank | |||
+ | Normal rank |
Revision as of 18:07, 18 June 2020
Cited in: "Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response" Research article published in Curr Cardiol Rep; 2020 04 21 ; 22 (5) 32.
Language | Label | Description | Also known as |
---|---|---|---|
English |
Gautret P, et al, Int J Antimicrob Agents (2020), cited as Ref 82 in DOI:10.1007/s11886-020-01292-3
|
Cited in: "Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response" Research article published in Curr Cardiol Rep; 2020 04 21 ; 22 (5) 32.
|
Statements
Q10356 (Deleted Item)
0 references
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial;105949. (English)
0 references
Gautret P
0 references
Lagier J-C
0 references
Parola P
0 references
Hoang VT
0 references
Meddeb L
0 references
Mailhe M
0 references